Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Increases Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,899 shares of the medical equipment provider’s stock after buying an additional 27 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Intuitive Surgical were worth $3,002,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. WCM Investment Management LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter worth approximately $575,536,000. International Assets Investment Management LLC boosted its holdings in Intuitive Surgical by 32,360.5% in the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock worth $231,721,000 after purchasing an additional 684,749 shares in the last quarter. Alphinity Investment Management Pty Ltd boosted its holdings in Intuitive Surgical by 113.2% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after acquiring an additional 677,455 shares during the period. J.P. Morgan Private Wealth Advisors LLC bought a new stake in shares of Intuitive Surgical in the third quarter valued at about $178,667,000. Finally, Quadrature Capital Ltd raised its position in Intuitive Surgical by 466.2% in the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock worth $99,601,000 after purchasing an additional 280,480 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ISRG. Raymond James raised their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research note on Thursday, January 25th. Jefferies Financial Group boosted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday. BTIG Research upped their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday. Truist Financial upped their price objective on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. Finally, Barclays increased their target price on shares of Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average target price of $396.17.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, VP Fredrik Widman sold 5,041 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the transaction, the vice president now directly owns 110 shares in the company, valued at approximately $43,677.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intuitive Surgical news, EVP Myriam Curet sold 4,318 shares of the firm’s stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $370.15, for a total value of $1,598,307.70. Following the completion of the transaction, the executive vice president now directly owns 189 shares in the company, valued at $69,958.35. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Fredrik Widman sold 5,041 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the transaction, the vice president now directly owns 110 shares in the company, valued at approximately $43,677.70. The disclosure for this sale can be found here. In the last quarter, insiders sold 248,418 shares of company stock worth $95,927,097. Company insiders own 0.80% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ ISRG traded up $8.74 on Tuesday, reaching $377.67. 788,134 shares of the company’s stock traded hands, compared to its average volume of 1,663,087. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The stock has a 50 day moving average price of $386.57 and a 200-day moving average price of $344.41. The firm has a market cap of $133.87 billion, a price-to-earnings ratio of 68.22, a P/E/G ratio of 5.69 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same period in the previous year, the business posted $1.00 EPS. Intuitive Surgical’s revenue was up 11.5% on a year-over-year basis. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 4.93 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.